6CM
CAMP icon

683 Capital Management’s CAMP4 Therapeutics CAMP Stock Holding History

683 Capital Management’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$476K Sell
108,000
-18,363
-15% -$87.2K 0.02% 186
2025
Q4 		$775K Buy
+126,363
New +$538K 0.03% 162

Other funds holding CAMP

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

683 Capital Management's CAMP Position: Q1 2026 in Review

683 Capital Management reduced its CAMP4 Therapeutics (CAMP) stake by 15% in Q1 2026, selling an estimated $87.2K and leaving 108,000 shares worth $476K. The position accounts for 0.02% of the portfolio, ranked #186.

683 Capital Management first reported a position in CAMP in Q4 2025 and has held it in 2 quarters since. The position peaked at $775K in Q4 2025. 46 funds tracked by Wall St. Rank hold CAMP as of Q1 2026.

  • 683 Capital Management held 108,000 shares of CAMP4 Therapeutics worth $476K as of Q1 2026.
  • 683 Capital Management sold 18,363 CAMP4 Therapeutics shares in Q1 2026, an estimated $87.2K.
  • CAMP4 Therapeutics made up 0.02% of 683 Capital Management's portfolio in Q1 2026, its #186 holding.
  • 683 Capital Management first reported a position in CAMP4 Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 683 Capital Management's CAMP4 Therapeutics position peaked at $775K in Q4 2025.
  • 46 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.